CEO Robin Vince highlighted a "solid financial performance" with earnings per share reaching $1.58, representing a 26% year-over-year increase. Total revenue reached $4.8 billion, up 6% year-over-year ...

Good morning, and welcome to the 2025 First Quarter Earnings Conference Call hosted by BNY. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer ...

Amazon's resilient business model, strong cash flow, and growth drivers like AI, Prime & advertising make it a compelling ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Tevogen Bio faces hurdles with unclear COVID-19 therapy demand, ambitious projections, and risks ahead. Click here to read an ...

Apple Inc.'s market value declines amid tariff controversy. Discover why its valuation remains unattractive and growth ...

Dr. Maguire is an ardent, experienced value investor. Most of his career has been spent as a healthcare executive and business owner, caring for patients diagnosed with cancer in coastal North ...

The 200DMA Signal suggests S&P 500 Index losses amidst U.S.-China tensions. Click for my look at technical triggers for the ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing ...

NVR faces short-term challenges but thrives on a 3.5M U.S. housing shortage. With a 25% upside, discover why it's a long-term ...

Recuresion Pharma (RXRX) stock and other AI-driven biotechs surge as FDA embraces computational models over animal testing ...

With inflation cooling and tariffs on pause, markets have found relief, but trade and economic uncertainty remains. TD Asset ...